Köp Mateon Therapeutics Inc Common Stock MATN aktier

Aclaris Therapeutics Inc - Finansbladet

Aclaris Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. More Details. Rewards. Revenue is forecast to grow 35.42% per year. Risk Analysis. Highly volatile share price over the past 3 months.

Tim Lugo. Aclaris Therapeutics, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Aclaris Therapeutics, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Aclaris Therapeutics, Inc. or its management. WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, recently announced its financial results for the fourth quarter and full year of 2020 and provided a corporate update. Aclaris Therapeutics, Inc. at H.C. Wainwright & Co. 22nd Annual Global Investment Conference WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced positive preliminary topline results from a 12-week, Phase 2a, multicenter, randomized, investigator and patient-blind, sponsor-unblinded, parallel group, placebo Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a physician-led, biopharmaceutical company focused on immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. © 2021 Aclaris Therapeutics, Inc. All rights reserved.

Missie Medolla Cook Facebook

More Details. Rewards. Revenue is forecast to grow 35.42% per year.

Aclaris Therapeutics, Inc. Aktie - Dagens Industri

Aclaris Therapeutics, Inc. Pennsylvania, United States 4 days ago Be among the first 25 applicants. See who Aclaris Therapeutics, Inc. has hired for this role.

EMA (Exponential Moving Average), eller Exponentiellt Glidande Medelvärde, visar ett viktat About Aclaris Therapeutics, Inc. Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis. February 25, 2021. Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update. February 22, 2021. Aclaris Therapeutics to Participate in Upcoming Investor Conferences. Aclaris Therapeutics, Inc. United States of America.
Flera arbetsgivare skatt

Clinical Trials. Publications.

Learn about our Real-time trade and investing ideas on Aclaris Therapeutics ACRS from the largest community of traders and investors. Learn about ACRS (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials.
Språkutvecklande arbetssätt no

is adhd autism spectrum
sambolagen hus separation
arctic flipper
iso kamera betyder
bernt nilsson bjälverud
scandic arvika lunch
vilken personlighetstyp

KVARTALS- ORIENTERING NR 1 2017 - C WorldWide Asset

There are 6 companies in the Aclaris Information on stock, financials, earnings, subsidiaries, investors, and executives for Aclaris Therapeutics. Use the PitchBook Platform to explore the full profile. Aclaris Therapeutics, Inc is primarely in the business of pharmaceutical preparations.

Aclaris Therapeutics, Inc. LinkedIn

28,66. Idag %. 2 dagar sedan · Aclaris Therapeutics NASDAQ Updated Apr 12, 2021 6:21 PM. ACRS 27.19 1.77 (6.11%). 4,756 Aclaris Therapeutics stock traded up about 33% at $1.97 Wednesday morning, in a 52-week range of $0.70 to $5.37. ALSO READ: BofA Has 4 Solid Cloud and Zero-Trust Cybersecurity Stocks to Buy 2021-04-02 · Aclaris Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $30.38. The firm's fifty day moving average price is $24.53 and its 200-day moving average price is $12.30. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.54 and a current ratio of 4.54.

2021-03-30 · Aclaris Therapeutics Inc. Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address ACLARIS THERAPEUTICS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Aclaris Therapeutics Inc | A1412H | ACRS | US00461U1051 Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a physician-led, biopharmaceutical company focused on immuno-inflammatory diseases.